2023 USCAST Virtual Public Meeting
USCAST held a virtual meeting on February 8, 2023, and over 200 attendees joined to hear about the vision and future goals for USCAST and the 2023 in vitro susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) recommendations. STIC were reviewed for piperacillin/tazobactam against Enterobacterales and Pseudomonas aeruginosa, various agents against A. baumannii, and aminoglycosides against Enterobacterales and P. aeruginosa. The links for the recordings and slide decks for the virtual meeting presentations are provided below for all interested parties to review.
Following the virtual meeting, the USCAST STIC recommendations were open for public comment for 60 days. This open comment period closed on April 30, 2023. USCAST is currently in the process of finalizing these STIC based on feedback received. We will update this site when the USCAST STIC are finalized. If you are interested in being alerted to these finalized USCAST STIC and/or other updates from USCAST, we encourage you to join our mailing list below.
Following the virtual meeting, the USCAST STIC recommendations were open for public comment for 60 days. This open comment period closed on April 30, 2023. USCAST is currently in the process of finalizing these STIC based on feedback received. We will update this site when the USCAST STIC are finalized. If you are interested in being alerted to these finalized USCAST STIC and/or other updates from USCAST, we encourage you to join our mailing list below.
|
|
|
|
Piperacillin/tazobactam breakpoints: Enterobacterales and P. aeruginosa Thomas Lodise, PharmD Executive Committee, USCAST Download Slides |
|
|
|
|
|
|
|
|
Under Construction: We’re currently updating the USCAST website, so some content is not current.